MedTrace Logo

Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease

NCT00982072 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2021-05-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effectiveness of tacrolimus (prograf) versus prednisolone for the treatment of nephrotic syndrome secondary to minimal change disease.

Conditions

  • Minimal Change Disease

Interventions

DRUG

tacrolimus

tacrolimus0.05mg/kg bd (levels 6-12ng/ml)

DRUG

prednisolone

Prednisolone 1mg/kg maximum 60mg od

Sponsors & Collaborators

  • Imperial College Healthcare NHS Trust

    lead OTHER

Principal Investigators

  • Megan Griffith, MBChBPhDFRCP · Imperial College NHS Trust

  • Tom Cairns, MBBSMRCP · Imperial College NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2019-10-10
Completion
2019-10-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00982072 on ClinicalTrials.gov